Authors:Nicolas Fraunhoffer, Carlos Teyssedou, Patrick Pessaux, Martin Bigonnet, Nelson Dusetti, Juan Iovanna
Photo of Nelson Dusetti taken from youtube.com
Sep 12, 2024, 17:36
Nelson Dusetti: A major advancement in transcriptomic signatures for predicting treatment sensitivity in pancreatic cancer
Nelson Dusetti shared on LinkedIn:
“We are thrilled to announce a major advancement in transcriptomic signatures for predicting treatment sensitivity in pancreatic cancer, now extended to metastatic patients through fine needle aspiration (FNA) biopsies. This development broadens the application of the Pancreas View transcriptomic signature, initially validated in operable patients, to include all pancreatic cancer patients, marking a significant step toward more personalized and effective treatments.”
Source: Nelson Dusetti/LinkedIn
More posts featuring Nelson Dusetti on oncodaily.com
Nelson Dusetti is Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12